Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues

AIDS Research and Human Retroviruses

Volumn 17, Issue 6, 2001, Pages 517-523

  Penn, Michael L ^a   Myers, Margaret ^a   Eckstein, Daniel A ^a   Liegler, Teri J ^a   Hayden, Matt ^a   Mammano, Fabrizio ^b   Clavel, François ^b   Deeks, Steven G ^c   Grant, Robert M ^a   Goldsmith, Mark A ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR;

ADAPTATION; ARTICLE; CELL COMPARTMENTALIZATION; CELL MATURATION; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPOTHESIS; LYMPHATIC SYSTEM DISEASE; LYMPHOCYTE COUNT; PATHOGENICITY; PRIORITY JOURNAL; TISSUE CULTURE; TONSIL; TREATMENT FAILURE; VIRUS ATTENUATION; VIRUS ISOLATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CULTURE TECHNIQUES; CYTOPATHOGENIC EFFECT, VIRAL; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LYMPHOCYTE DEPLETION; LYMPHOID TISSUE; RECOMBINATION, GENETIC; TONSIL;

EID: 0034914207     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220151126580     Document Type: Article

References (39)

1. Viral proteinases
2. Mutational analysis of human immunodeficiency virus type 1 protease suggests functional homology with aspartic proteinases
3. The retroviral enzymes
4. Proteolytic processing and particle maturation
5. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection
6. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation
7. The HIV-1 protease as a therapeutic target for AIDS
8. HIV protease inhibitors
9. Antiretroviral therapy for HIV infection: Promises and problems
10. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection
11. The use of combination antiretroviral therapy in HIV-infected patients
12. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
13. Resistance to HIV protease inhibitors
14. HIV treatment failure: Testing for HIV resistance in clinical practice
15. Failure of HIV-1 protease inhibitors to fully suppress viral replication. Implications for salvage therapy
16. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
17. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors
18. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
19. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites
20. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within Gag/Pol polyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1
21. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor
22. Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of re-sistance mutations in the presence and absence of the drug
23. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
24. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
25. Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed in-fections
26. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
27. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro
28. Resistance-assisted loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and Gag coevolution in protease inhibitor-treated patients
29. Poduction of acquired immunodeficiency syndrome-associated retrovirs in human and nonhuman cells transfected with an infectious molecular clone
30. Experimental HIV infection of human lymphoid tissue: Correlation of CD4+ T-cell depletion and virus syncytium-inducing/non-syn-cytium-inducing phenotype in histocultures inoculated with laboratory strains and patient isolates of HIV type 1
31. CXCR4 utilization is sufficient to trigger CD4+ T-cell depletion in HIV-1-infected human lymphoid tissue
32. Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease
33. Protease inhibitor-resistant HIV-1 from patients with preserved CD4 cell counts is cytopathic in activated CD4 T lymphocytes
34. Changes in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals
35. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates
36. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality
37. The role of viral diversity in HIV pathogenesis
38. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population
39. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection